USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations
Rubicon Research Ltd 路 Others (Uncategorized) 路 30 Oct 2026, 5:53 am
USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations The USFDA conducted an unannounced comprehensive GMP and product-filing inspection at Rubicon Research's Ambernath manufacturing facility from 21st Oct'26 to 29th Oct'26. The regulator issued a Form 483 with five observations: three concerning system improvements and two regarding the product application under review. All observations are procedural with no data integrity issues. Across other sites, R&D units in Canada and Thane hold EIRs with zero observations, New Jersey holds VAI status, while responses have been submitted for Pithampur and Satara inspections.
Original exchange filing (PDF)
More announcements from Rubicon Research Ltd
- Disclosure under Regulation 30 of SEBI LODR Regulations, 2015 (SEBI Regulations) w.r.t update on the Scheme of Merger between Rubicon Research Ltd and KIA Health Tech Pvt Ltd 路 14 Nov 2026
- Transcript of Earnings Call -Q2 - FY 2026-27 路 12 Nov 2026
- Audio Recording of Earnings confrence call for the Quarter ended 30th September, 2026 路 06 Nov 2026
- Monitoring Agency Report - Q2 ended September 2026 路 05 Nov 2026
- Investor Presentation for Q2 2026-27 路 05 Nov 2026
- Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Outcome of the Board Meeting held on November 5, 2026 路 05 Nov 2026
- Grant of Stock Options under Rubicon Research LImited Stock Option Plan 2026 路 05 Nov 2026
